Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient advocacy groups requested an expanded access programme to both provide lenali...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen, Christine, Reece, Donna E, Siegel, David, Niesvizky, Ruben, Boccia, Ralph V, Stadtmauer, Edward A, Abonour, Rafat, Richardson, Paul, Matous, Jeffrey, Kumar, Shaji, Bahlis, Nizar J, Alsina, Melissa, Vescio, Robert, Coutre, Steven E, Pietronigro, Dennis, Knight, Robert D, Zeldis, Jerome B, Rajkumar, Vincent
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2009
Subjects:
Haematological Malignancy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2728892/
https://ncbi.nlm.nih.gov/pubmed/19545290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07728.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items